New peer-reviewed, scientific study shows Vyleesi enhances sexual brain processing in premenopausal women with HSDD. Click here to learn more ›

Palatin Technologies to Present at the 36th Annual Canaccord Genuity Growth Conference

CRANBURY, N.J., Aug. 8, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that Carl Spana, the Company’s President & Chief Executive Officer, will present at the 36th Annual Canaccord Genuity Growth Conference on Thursday, August 11th, 2016 at 1:00 p.m. Eastern time. The conference is being held at the InterContinental Boston, Boston, MA August 10-11, 2016.

About Palatin Technologies
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin’s website at http://www.palatin.com

SOURCE Palatin Technologies, Inc.

Related Links

http://www.palatin.com

Scroll to Top